Evidence map›Paper›PMID 36723821›Full record

ArticleMolecular and cellular biochemistry2023

Multimerin 1 aids in the progression of ovarian cancer possibly via modulation of DNA damage response and repair pathways.

Abhinav Saini, Vikrant Kumar, Anil Kumar Tomar, Alpana Sharma, Savita Yadav

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Abhinav Saini *Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 11029, India.
Vikrant Kumar *Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 11029, India.
Anil Kumar TomarDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 11029, India.
Alpana SharmaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, 11029, India.
Savita YadavDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 11029, India. savita11@gmail.com.
All India Institute of Medical Sciences · IN

Funding

Science and Engineering Research Board CRG/2020/002194
6 · The paper itself

Abstract

Ovarian cancer is one of the leading causes of deaths among women. Despite advances in the treatment regimes, a high rate of diagnosis in the advanced stage makes it almost an incurable malignancy. Thus, more research efforts are required to identify potential molecular markers for early detection of the disease and therapeutic targets to augment the survival rate of ovarian cancer patients. Previously, in this context, we identified dysregulated expression of multimerin 1 (MMRN1) in ovarian cancer. To elucidate the relationship between MMRN1 expression and ovarian cancer progression, siRNA-based MMRN1 knockdown was employed and various cell assays were performed to study its effect on ovarian cancer cells. In addition, network of dysregulated proteins was identified by quantitative proteomics and associated pathways were explored by bioinformatics analysis. MMRN1 silencing showed a significant reduction in cell viability, adhesion, migration, and invasion and a high frequency of cell apoptosis. Label-free quantitative proteomics and in-depth statistical analysis identified 448 dysregulated proteins, majority of which were overexpressed in MMRN1 knockdown cells. The pathways overrepresented in ovarian cancer were DNA replication, mismatch repair, nucleotide excision repair, and cell cycle regulation. Conclusively, the findings of this study suggest that MMRN1 aids in the progression of ovarian cancer via modulation of DNA damage response and repair pathways.

Indexed as

Blood ProteinsOvarian NeoplasmsCell Line, TumorDNA DamageDNA RepairFemaleHumansBlood ProteinsmultimerinCancer progressionDifferential proteomicsDNA damage responseGene silencingMMRN1Ovarian cancer

Identifiers

PMID36723821
OpenAlexW4318755830

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.